Zydus Cadila receives final approval from USFDA for Vortioxetine Tablets

Zydus Cadila receives final approval from USFDA for Vortioxetine Tablets Ahmedabad, India, 18 September, 2021 Zydus Cadila has received final approval from the USFDA to market Vortioxetine Tablets in the strengths of 5 mg, 10 mg, 20 mg (US RLD: Trintellix Tablets). Vortioxetine is used to treat depression. It works by helping to restore the balance of a certain natural substance (serotonin) in the brain. Vortioxetine is an SSRI (selective serotonin reuptake inhibitor) and serotonin receptor modulator. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 322 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcar e therapies. The group employs over 23 000 people worldwide and is dedicated to creating healthier communities globally. ***

The release as fetched from its publisher. zyduslife.com ↗